Navigation Links
PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
Date:4/30/2013

$
50,611$
43,301% of total service revenue11.1%12.2%Gross profit$
20,187$
8,200Gross margin % of service revenue39.9%42.0%Perceptive Informatics (PI)Service revenue$
,495$
49,319% of total service revenue13.6%13.8%Gross profit$
26,884$
21,495Gross margin % of service revenue43.7%43.6%Total service revenue$
454,493$
355,992Total gross profit$
42,576$
4,547Gross margin % of service revenue31.4%32.2%Revenue by Geography The Americas$
231,155$
5,672Europe, Middle East & Africa161,747140,315Asia/Pacific61,59150,005Total service revenue$
454,493$
355,992Quarterly Supplemental Financial DataService revenue$
454,493$
355,992Reimbursement revenue68,95856,037Investigator fees118,05164,969Gross revenue$
41,502$
476,998Days sales outstanding3656Capital expenditures$
8,741$
,650 

 

 PAREXEL International CorporationSegment InformationUnauditedNine Months EndedNine Months Ended(in thousands)3/31/20133/31/2012Clinical Research Services (CRS)Service revenue $
960,134$
746,652% of total service revenue75.5%74.4%Gross profit$
250,671$
207,541Gross margin % of service revenue26.1%27.8%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue$
48,236$
7,404% of total service revenue11.7%11.7%Gross profit$
59,673$
48,741Gross margin % of service revenue40.3%41.5%Perceptive Informatics (PI)Service revenue$
2,944$
39,841% of total service revenue12.8%13.9%Gross profit$
8,324$
55,897Gross margin % of service revenue41.9%40.0%Total service revenue$
,271,314$
,003,897Total gross profit$
378,668$
312,179Gross margin % of service revenue29.8%31.1%Revenue by Geography The Americas$
38,634$
443,927Europe, Middle East & Africa450,125408,306Asia/Pacific182,555151,664Total service revenue$
,271,314$
,003,897 

CONTACTS:James Winschel, Senior Vice President and Chief
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. PAREXEL International to Present at Morningstar Conference
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
10. UV Flu Technologies Expands Its International Footprint
11. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Follow us ... to revolutionize the world has attracted diverse players ... small start-ups. The early years of nanotechnology development ... due to the high risks involved, which deterred ... for this evolving technology have been growing over ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
(Date:9/19/2014)... September 19, 2014 Biotech companies ... of emerging drug systems and advanced Laboratory Instrumentation. Companies ... Company (NYSE: BDX ), Thermo Fisher Scientific ... (NASDAQ: RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... 10 Bioheart, Inc., (OTC Bulletin Board: BHRT) a company ... diagnose and treat heart failure and other cardiovascular diseases announced ... development has been invited to participate in the 2009 World ... , Ms. Comella will speak on the concurrent ...
... , , , ... , Current studies show that only four ... point of care. By 2019, the Congressional Budget Office (CBO) estimates ... to about 90 percent , EHRs will create ...
... ATLANTA and LONDON, Sept. 10 CryoLife ... device and cardiovascular tissue processing company, today announced the first clinical ... received CE mark approval in August 2009. BioFoam was used in ... to promote hemostasis (a complex process that stops bleeding) by sealing ...
Cached Biology Technology:Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 2Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 2Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 4CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... new resource unveiled today by researchers from several ... Dublin provides both experienced and aspiring researchers with ... and operate robots made from soft, flexible materials. ... laser cutters, and other advances in manufacturing technology, ... field. Using principles drawn from conventional rigid robot ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... A new type of protein discovered by Queen’s University researchers ... as those that cause food poisoning and typhoid. , ... YihE or RdoA ?a team of professors and students from ... up possibilities for new drug development. , “Our ...
... from the Virginia Commonwealth University Massey Cancer Center ... of Cancer Research's annual meeting suggesting the potential ... leukemia (CLL). , In this study, ... of translational research, interactions between bortezomib and romidepsin ...
... found astonishing evidence that the lifelong use of two ... by four years compared to people who are monolingual. ... literature examining how lifestyle factors such as physical activity, ... in later years of life. Cognitive reserve refers to ...
Cached Biology News:Protein discovery targets antibiotic-resistant bacteria 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 3
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: